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Abstract: Degradation products of titanium implants include free ions, organo-metallic 
complexes, and particles, ranging from nano to macro sizes. The biological effects, especially 
of nanoparticles, is yet unknown. The main objective of this study was to develop Ti-protein 
antigens in physiological solutions that can be used in testing of cellular responses. For this 
purpose, 0.1% TiO2 nanoparticles less than 100 nm were mixed with human serum albumin 
(HSA), 0.1% and 1%, in cell culture medium (DMEM, pH 7.2). The Ti concentrations in the 
resulting solutions were analyzed by inductively coupled plasma mass spectrometry. The stabil-
ity of the nanoparticles in suspension was analyzed by UV-vis spectrophotometer and Dynamic 
Light Scattering. The concentration of Ti in suspension was dependent on the presence and 
concentration of HSA. Albumin prevented high aggregation rate of TiO2 nanoparticles in cell 
culture medium. It is shown that nano TiO2-protein stable aggregates can be produced under 
physiological conditions at high concentrations, and are candidates for use in cellular tests.
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Introduction
Titanium (Ti) is widely used in medicine and dentistry, either in its pure form or 
in alloys, due to the combination of physical, chemical and biological properties 
(Scharnweber et al 2002). Titanium is employed in eg, joint prostheses, fracture ﬁ  xa-
tion devices, endovascular stents, pacemaker enclosures, and dental materials (Peters 
et al 1984; Yamauchi et al 2000; Stoeckel et al 2004; Tschernitschek et al 2005).
The high corrosion resistance of Ti is due to a strongly passivating oxide layer 
(Hallab et al 2004). Nevertheless, Ti degrades under mechanical stress, abrasion, low 
pH and low oxygen level (Tschernitschek et al 2005). It is established that Ti-based 
implants release particles and ions to the surrounding tissue and ﬂ  uids, as has been 
demonstrated with hip implants (Mckellop et al 1990; Brien et al 1992), as well as 
with miniplates used for jaw fractures (Schliephake et al 1993; Torgersen et al 1995), 
and even unloaded dental implants (Arys et al 1998; Flatebø et al 2006). However, 
the biological consequences of the degradation products, ions, nano- or micrometer 
sized particles, remain unclariﬁ  ed.
Based mostly on case reports, it has been suggested that hypersensitivity to Ti is 
associated with implant loosening (Wooley et al 1996; Matthew and Frame 1998), 
or skin reactions (Peters et al 1984; Yamauchi et al 2000; Tamai et al 2001; High 
et al 2006; Thomas et al 2006; Watanabe et al 2006). Diagnosis of contact allergy 
to metals usually relies on combination of anamnestic information and in vivo tests 
such as a epicutaneous patch test (Hallab et al 2001; Granchi et al 2006), and – in 
some instances – ex vivo tests such as a Lymphocyte Stimulation Test (LST) on 
cells from blood samples (Hallab et al 2001). Hypersensitivity tests have not been 
established for Ti (Lalor et al 1991; Hallab et al 2001; Klein et al 2004) and Ti is International Journal of Nanomedicine 2008:3(1) 70
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not included in standard commercial routine patch test 
series. Various titanium compounds, such as Ti-salts (Lalor 
et al 1991) and TiO2 micrometer sized particles (Thomas 
et al 2006) have been tried in hypersensitivity testing, but 
optimal Ti antigens are not established yet (Bircher and 
Stern 2001).
The ex vivo test, LST, requires cell culture techniques and 
bioavailable Ti at physiological culture conditions (Hallab 
et al 2001). The difﬁ  culty with Ti is that this metal is not 
readily soluble at physiological pH, as nickel salts are (Lalor 
et al 1991; Hallab et al 2000; Hallab et al 2004). Had relevant 
and stable Ti-substances been available, the applicability 
of patch testing (Granchi et al 2006) and LST (Hallab et al 
2001) could be improved for Ti.
Nanoparticles, with dimensions less than 100 nm, interact 
differently with various proteins and subsequently with cells 
when compared with the conventional size particles (Liu and 
Webster 2006). Surface functionalization of gold nanopar-
ticles has been used to develop diagnostic and treatment tools 
(Shenoy et al 2006). Surface modiﬁ  cation of nanoparticles 
can be achieved by protein binding.
Albumin has been shown to be dominant in binding Ti 
in vivo (Hallab et al 2000). It is the most prevalent protein 
in plasma (approximately 42 g/l for adults) with important 
functions such as metal binding, transport, and in providing 
colloidal osmotic pressure (Vander et al 1998).
By simulating the model of metal-protein binding in 
vivo, the aim of the present study was to develop Ti-protein 
antigens based on titanium dioxide nanoparticles that can be 
useful for testing cellular responses in diagnosis of human 
Ti hypersensitivity.
Materials and methods
Materials
Commercially pure titanium dioxide (TiO2) nanoparticles, 
99.9%, consisting of the crystallographic forms anatase 
and rutile (MW05084, Sigma-Aldrich, St. Louis, USA) 
were used. The powder particles have an average diameter 
100 nm. The speciﬁ  c surface area of the TiO2 nanopowder, 
determined by the Brunauer-Emmet-Teller (BET) method 
according to the nitrogen adsorption (ASAP 2020 Volumetric 
Adsorption, Micromeritics), was 19.6 m2/g. The cell culture 
medium used was Dulbecco’s Modiﬁ  ed Eagle’s Medium 
(DMEM, Sigma-Aldrich, D6046, UK). The medium is a 
high ionic strength solution and contains low amounts of 
glucose and amino acids. Commercially available human 
serum albumin (HSA) (96%–99%, Sigma-Aldrich, SL04521, 
St. Louis, USA) was used.
Methods
Preparation of potential antigens and determination 
of Ti-concentrations
Several suspensions were prepared by mixing the reagents in 
DMEM. A suspension was prepared by mixing 50 mg TiO2 
in 50 ml DMEM for a concentration of 0.1% TiO2. Different 
quantities of HSA – 50 mg (0.1%) and 500 mg (1%) – were 
added. Control suspensions of 0.1% TiO2 nanoparticles in 
DMEM (0% HSA) were prepared. The suspensions were 
placed in a shaking machine in an incubator at 37 °C for 
8 days in order to assess the effect of exposure time between 
nano-TiO2 and HSA. Aliquots of 2 ml were taken from each 
solution, after 1 h, 24 h, and 8 days. The samples were cen-
trifuged at 3000 rpm (15 min), and sterile ﬁ  ltered (Millex 
HV ﬁ  lters, Millipore, Carrigtwohill, Co. Cork, Ireland, pore 
size 0.45 µm). The assays ran 6 times.
The total concentration of titanium in the ﬁ  ltered suspen-
sions was determined Inductively Coupled Plasma - Mass 
Spectrometry (ICP-MS). The instrument (Element 2, Thermo 
Finnigan, Bremen, Germany) used a high resolution, magnetic 
sector ﬁ  eld. Colloidal suspensions of nanoparticles with 
average sizes of 400 nm have been shown to be totally ionized 
in the argon plasma, which holds a temperature of nearly 
8000 K (Degueldre and Favarger 2003). The instrument was 
operated at medium resolution (R = 4000) for the isotopes Ti47 
and Ti49, and the resulting signal count at the mass detector 
was calibrated to represent the total Ti-concentration in the 
sample. The sample aliquots (0.5 ml) were diluted by a factor 
of 100–200 with ultra-clean 1% nitric acid before measure-
ments. An internal standard of indium (1 µg/l) was added to 
all the samples to monitor and to correct for any instrumental 
ﬂ  uctuations. Calibration was performed by standard addition 
using calibrating solutions made from a 1000 mg/l stock 
standard solution (Merck, Darmstadt, Germany). The method 
detection limit for the Ti analysis was 0.56 µg/l. The accuracy 
of the analytical method was monitored by a reference material 
(Seronorm Trace Elements Serum level 1, lot MI0181, Sero 
AS, Billingstad, Norway) with a recommended Ti-value of 
2.6 µg/l. We found a median value of 2.55 (n = 10).
Transmission electron microscopy (TEM)
Suspensions with 0.1% TiO2 nanoparticles in DMEM only 
and in DMEM + 0.1% HSA were prepared at the same con-
ditions (shaking machine; incubator 37 °C) as previously 
mentioned. The suspensions were shaken for 4 days. The 
samples prepared for TEM images were not centrifuged and 
sterile ﬁ  ltered in order to visualize the TiO2 nanoparticles and 
aggregate formation. One drop (10 µl) from each suspension, International Journal of Nanomedicine 2008:3(1) 71
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diluted 10 times, was placed on a Cu mesh grid. The excess 
liquid was removed immediately by ﬁ  lter paper. The samples 
were lyophilized overnight at room temperature, and ana-
lyzed using a transmission electron microscope (JEM-1230) 
at electron emission of 60 kV.
Physicochemical characterization: Stability of TiO2 
nanoparticles in suspension
Dynamic light scattering (DLS) was used to measure the 
hydrodynamic diameter of aggregates in suspension. The 
particles in suspension are subject to the thermal Brownian 
motion and the rate of particles movement depends upon their 
size (Tkachenko et al 2006). Suspensions of 0.1% TiO2 in 
DMEM and TiO2 with 0.1% and 1% of HSA in DMEM were 
prepared, shaken for 2 hours, ultrasonicated for 30 sec, and 
analyzed. The measurements were conducted on the Zetasizer 
NS (Malvern Instruments Ltd, UK).
The TiO2 nanoparticles sedimentation rate was deter-
mined by monitoring the absorbance at 337 nm (the wave-
length of maximum absorbance of the solid) as a function 
of time by UV-vis spectrophotometer (Perkin-Elmer, Model 
554, Germany). The TiO2 suspensions were prepared in the 
same manner as described for DLS study and analyzed before 
and after sterile ﬁ  ltration (pore size 0.45 µm). All measure-
ments were made at 25 °C. Square cuvettes with 1 cm light 
path were used. The center of the light beam passed through 
the cuvette 1.5 cm above its bottom.
Statistical analysis
Statistical analysis was performed using SPSS version 
13.0. P-values less than or equal to 0.05 were considered 
signiﬁ  cant. Friedman test was used for time-line differ-
ences and Mann-Whitney test for the two levels of albumin 
concentrations.
Results
The preparation of antigens in the ﬁ  rst part of our study was 
proceeded for a period of 8 days, in orders to asses the effect 
of the exposure time between nano-TiO2 and albumin on Ti 
concentration. Based on obtained results, the study contin-
ued with TEM imaging and the determination of stability of 
nano-TiO2 antigens in suspension.
The ﬁ  ltered suspensions, with no HSA, gave a low median 
Ti concentration (by ICP-MS), below 1 µg/l, and unaffected 
by exposure time. The presence of HSA increased the concen-
tration of Ti by 2–3 orders of magnitude when compared to 
controls (suspensions without HSA). Longer exposure time 
raised also the Ti concentrations in suspensions with 0.1 and 
1% HSA (Figure 1). Differences between Ti concentrations 
with 0.1% HSA and 1% HSA were statistically different for 
all time points, except at day 8.
The TEM images of the unﬁ  ltered suspensions revealed 
that the individual TiO2 nanoparticles were spherical, with 
diameters ranging from 20 to more than 100 nm. The TiO2 
nanoparticles formed typical aggregates in both suspensions, 
with and without albumin (Figures 2a and 2b).
The DLS measurements results showed that TiO2 
nanoparticles formed large aggregates in DMEM without 
HSA, but the mean aggregate size was about 1/5 in presence 
of HSA. After ﬁ  ltration, the mean aggregate size was about 
half of the unﬁ  ltered suspensions (Table 1). The evolution 
of TiO2 aggregates size in DMEM with 1% HSA revealed a 
slow growth over 20 h period (regression model: mean size 
(nm) = 1.46 time (h) + 210; R2 = 0.83).
The sedimentation rate results revealed that the TiO2 
aggregates sedimented rapidly (5 h) in absence of HSA, 
whereas in presence of HSA, the sedimentation rate was 
close to zero (Figure 3). After ﬁ  ltration, the TiO2 aggregates 
were stable in suspension all along a 20 h period (Figure 3). 
In DMEM without HSA, after ﬁ  ltration, the TiO2 nanopar-
ticles were not detectable by either Zetasizer or the UV-vis 
spectrophotometer.
Discussion
The results presented in this study show that the combination 
of human serum albumin and Ti in the form of nanoparticles 
raises the bioavailability of Ti in suspension, most likely 
through a metal-protein association.
I
Figure 1 Ti concentration as a function of incubation time (median, whiskers 
represent quartiles) in DMEM after mixing TiO2 nanoparticles with different 
concentrations of human serum albumin (HSA). p-values with vertical arrows: 
comparisons between the results with 0.1 and 1% HSA; p-values with horizontal 
arrows: Friedman’s test across the time points.International Journal of Nanomedicine 2008:3(1) 72
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Using nanoparticles to develop a potential diagnostic 
reagent for hypersensitivity testing is new and clinically 
appropriate because nanometer sized wear products have 
been found in tissues surrounding implants (Buscher et al 
2005). Titanium dioxide nanoparticles have greater potential 
toxic effect on cells than the conventional size particles (Chen 
et al 2006; Long et al 2006).
When compared with the micrometer-sized and easily 
detectable particles, the nanoparticles have larger speciﬁ  c 
surfaces and different physiochemical properties, which 
mean higher surface energy (Long et al 2006). Consequently, 
their interaction with cell membrane, cell structure, or cell 
activity may differ from the larger-size particulate matter 
(Long et al 2006).
Our results suggest that TiO2 nanoparticles, which 
aggregate and sediment rapidly in cell culture medium, 
are more stable in suspensions when they are in presence 
of HSA. This increased stability could be due to protein 
adsorption onto the surface of TiO2 nanoparticles or aggre-
gates (Klinger et al 1997; Oliva et al 2003). Moreover, steric 
repulsive forces caused by the protein chain reduce the 
net attractive interactions between particles, and thus alter 
the aggregation rate (Tirado-Miranda et al 2003; Limbach 
et al 2005). The presence of albumin slowed down the 
aggregate settling as shown by the sedimentation rate test, 
and raised the Ti concentration orders of magnitude even 
after ﬁ  ltration.
In presence of HSA, the mean aggregate size, as revealed 
by DLS, was slightly smaller than the pore size of 450 nm 
and thus most of the aggregates passed through the ﬁ  lter 
membrane (Table 1). These results are in concordance with 
results from the quantitative chemical analyses (ICP-MS) 
showing high ﬁ  nal Ti concentration in the samples (Figure 1). 
Furthermore, the effect of HSA on the reducing the aggregate 
size of TiO2 nanoparticles in suspensions is supported by 
our sedimentation study (Figure 3). Ultrasonication used for 
30 sec of TiO2-albumin suspensions showed also an effect on 
clustering size, by breaking down the big aggregates.
Few studies have been done on the colloidal stability of 
nanoparticles in cell culture media. Our results are in accor-
dance with Long et al (2006) who revealed that DMEM affects 
the rate of aggregation and consequently the size of clusters. 
In solution with high ionic strength without proteins, such as 
DMEM medium, the rate of aggregation is high, leading to 
Figure 2 Transmission electron microscopy (TEM) images of typical TiO2 nanoparticle aggregates in DMEM. TiO2 nanoparticles aggregate in both suspensions without (a)
and with 0.1% human serum albumin (HSA) (b). Pictures are taken from unﬁ  ltered suspensions, due to the difﬁ  culty of ﬁ  nding the characteristic aggregates in ﬁ  ltered 
suspensions.
Table 1 Mean hydrodynamic diameter for TiO2 after 2 h of 
shaking (n = 3)
Sample  Mean hydrodynamic diameter (nm) ± SD
 Before  ﬁ  ltration  After ﬁ  ltration
TiO2/DMEM 2765  ± 124  Not detected
TiO2 + 0.1%  446 ± 26  215 ± 1.7
HSA/DMEM
TiO2 + 1%  430 ± 23  216 ± 1
HSA/DMEMInternational Journal of Nanomedicine 2008:3(1) 73
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fast sedimentation (Gomez-Lopera et al 2006; Phenrat et al 
2007). However, if HSA is present, the adsorption of the 
protein onto TiO2 surfaces is almost independent of the ionic 
strength (Oliva et al 2003). The binding mechanisms of the 
TiO2-albumin interaction need more research.
It can be assumed that the TiO2 nanoparticles behave in a 
similar manner in vivo, making aggregates and binding to pro-
teins. This supports the idea that the metal released by implant 
degradation does not exist as unbound ionic or colloidal forms 
in serum but bound to serum proteins (Hallab et al 2000).
Since our potential antigens could be prepared already 
after 2 h of shaking, we recommend using these fresh sus-
pensions, in hypersensitivity testing, instead of those mixed 
for 8 days.
The biological reactivity of the new possible antigens 
is now being pursued in Lymphocyte Stimulation Test 
(LST). More tests needs to be done in order to standardize 
the method.
Conclusions
The TiO2 nanoparticle-albumin antigen could be clinically 
relevant as it mimics degradation products of Ti-based 
implants. Albumin has an important role in the colloidal 
stability of TiO2 nanoparticles in suspension, and thus, on 
the bioavailability of Ti for cellular tests. The applicability 
of the substances in clinical testing of hypersensitivity has 
to be elucidated.
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